Bavarian Nordic A/S (BVNRY) Stock Price, News & Analysis

Company Overview

Bavarian Nordic A/S is a fully-integrated biotechnology company focused on vaccination technology. The company’s work is built around two primary platforms that provide numerous benefits to the health industry and individuals. The company’s primary technology is MVA-BN which stands for Modified Vaccine Ankara-Bavarian Nordic. This vaccination platform is a non-replicating platform, meaning that live-virus vaccines cannot reproduce and spread within the host. This is central to the platform's high tolerance rate. MVA-BN is approved as a smallpox and monkeypox vaccine in the US, Canada, and the EU. It is also included in the US Strategic National Stockpile and is being used worldwide to control the 2022 Monkeypox outbreak.

Bavarian Nordic is headquartered in Hellerup, Denmark with manufacturing sites in Denmark and Germany. The company maintains offices in Switzerland, the UK, Japan, and North Carolina in the United States. The company was incorporated in 1992 and had 4 approved products under 7 brand names available for use. Its MVA-BN non-replicating smallpox and monkeypox vaccines are available under the IMVAMUNE, IMVANEX and JYNNEOS names.

The company’s second platform is the Vaccinia-Fowlpox-TRICOM platform for treating cancers. The platform can be targeted to attack specific markers found in numerous cancers. The company’s other marketable vaccines are Rabipur for rabies, MVABEA for Ebola and Marburg Hemorrhagic fever, and Encepur for tick-borne encephalitis.

The company’s pipeline has 4 potential candidates for the market. These include a freeze-dried version of MVA-BN for smallpox, MVA-BN for RSV (respiratory infection), and TAEK-VAC for certain cancers. The company’s COVID-19/SARS vaccine boosters have shown effectiveness 6 months after dosing. 

Written by Jeffrey Neal Johnson

Key Stats

• Today's Range: $9.13 to $9.30
• 50-Day Range: $8.13 to $9.63
• 52-Week Range: $6.86 to $14.60
• Volume: 5,030 shs
• Average Volume: 6,215 shs
• Market Capitalization: $2.19 billion
• P/E Ratio: 13.05
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BVNRY Stock Analysis - Frequently Asked Questions

How have BVNRY shares performed this year?

Bavarian Nordic A/S's stock was trading at $8.7060 at the start of the year. Since then, BVNRY stock has increased by 6.2% and is now trading at $9.25.
View the best growth stocks for 2025 here.

How do I buy shares of Bavarian Nordic A/S?

Shares of BVNRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 1/22/2025
• Next Earnings (Estimated): 3/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:BVNRY
• CUSIP: N/A
• CIK: N/A
• Web: www.bavarian-nordic.com
• Phone: (453) 326-8383
• Fax: 45-3326-8380
• Employees: 1,379
• Year Founded: 1994

Profitability

• EPS (Most Recent Fiscal Year): $0.69
• Trailing P/E Ratio: 13.05
• Forward P/E Ratio: 13.81
• P/E Growth: N/A
• Net Income: $214.20 million
• Net Margins: 18.33%
• Pretax Margin: 18.51%
• Return on Equity: 10.65%
• Return on Assets: 7.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.69
• Quick Ratio: 0.98

Sales & Book Value

• Annual Sales: $1.02 billion
• Price / Sales: 2.13
• Cash Flow: $2.00 per share
• Price / Cash Flow: 4.62
• Book Value: $6.41 per share
• Price / Book: 1.44

Miscellaneous

• Outstanding Shares: 236,500,000
• Free Float: N/A
• Market Cap: $2.19 billion
• Optionable: Not Optionable
• Beta: 1.65